← SynDRA
PRAMIPEXOLE
SynDRA canonical compound SYN0002707 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | DRD3 |
| Mechanism of action | Dopamine receptor agonist |
| Indication | Parkinson's Disease |
| Disease area | neurology/psychiatry |
All known targets
- DRD2
- DRD3
- DRD4
- ADRA2A
- ADRA2C
- HTR2A
- HTR1D
- ADRA2B
- HTR1B
- HTR1A
- HRH4
- HTR2C
Mechanisms of action (all sources)
- Dopamine receptor agonist
- DRD2 AGONIST
- D2-like dopamine receptor agonist
- DRD3 AGONIST
- DRD4 AGONIST
- DRD3 MODULATOR
- DRD2 MODULATOR
Drug classes
- Dopamine Agonists
- Anti-Dyskinesia Agents
- Antioxidants
- Antiparkinson Agents
- Central Nervous System Agents
- Dopamine Agents
- Neurotransmitter Agents
- Protective Agents
- Nonergot Dopamine Agonist
ATC classes
- N04B · DOPAMINERGIC AGENTS
Cross-references
Synonyms
- pramipexole hydrochloride
- pramipexole hydrochloride hydrate
- sifrol
- oprymea
- (S)-Pramipexole
- mirapexin
- pramipexole dihydrochloride
- pramipexole dihydrochloride monohydrate
- pramipexole HCl
- pramipexol dihydrobromide
- Pramipexol
- Ctc-501
- NSC-760426
- SUD-919CL2Y
- SUD919CL2Y
- U-98528E
- Neliprax
- Pipexus
- Mirapex
- Pramipexolum
- Mirapex (TN)
- Mirapexin (TN)
- Pramipexole [USAN:INN]
- SND-919
- Sifrol(TN)
- Pramipexole (USAN/INN)
- (-)-Pramipexole
- (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
- (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
- (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
- (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
- 111GE001
- 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
- 2-amino-6-propylaminotetrahydrobenzothiazole
- CTC-501
- NSC 760426
- SUD 919CL2Y
- (-) Pramipexole
Reported adverse events
- Nausea
- Somnolence
- Hypotension
- Dystonia
- Hallucination
- Dyskinesia
- Insomnia
- Akathisia
- Amnesia
- Asthenia
- Bursitis
- Constipation
Look up PRAMIPEXOLE in the interactive SynDRA portal →